0.0924
price down icon1.70%   -0.0016
 
loading
Schlusskurs vom Vortag:
$0.094
Offen:
$0.096
24-Stunden-Volumen:
1.34M
Relative Volume:
0.44
Marktkapitalisierung:
$6.12M
Einnahmen:
$1.47M
Nettoeinkommen (Verlust:
$-97.61M
KGV:
-0.062
EPS:
-1.49
Netto-Cashflow:
$-80.90M
1W Leistung:
-18.09%
1M Leistung:
-0.65%
6M Leistung:
-51.11%
1J Leistung:
-73.01%
1-Tages-Spanne:
Value
$0.0844
$0.096
1-Wochen-Bereich:
Value
$0.0844
$0.14
52-Wochen-Spanne:
Value
$0.082
$0.3468

Lyra Therapeutics Inc Stock (LYRA) Company Profile

Name
Firmenname
Lyra Therapeutics Inc
Name
Telefon
617-373-4600
Name
Adresse
480 ARSENAL WAY, WATERTOWN, MA
Name
Mitarbeiter
30
Name
Twitter
@LyraTx
Name
Nächster Verdiensttermin
2025-03-12
Name
Neueste SEC-Einreichungen
Name
LYRA's Discussions on Twitter

Vergleichen Sie LYRA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LYRA
Lyra Therapeutics Inc
0.0924 7.47M 1.47M -97.61M -80.90M -1.49
Biotechnology icon
ONC
Beigene Ltd Adr
238.76 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.03 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2548 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.85 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.69 5.92B 0 -153.72M -103.81M -2.00

Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-05-07 Herabstufung BofA Securities Buy → Underperform
2024-05-07 Herabstufung H.C. Wainwright Buy → Neutral
2024-05-07 Herabstufung Jefferies Buy → Hold
2024-05-06 Herabstufung William Blair Outperform → Mkt Perform
2023-10-06 Fortgesetzt BTIG Research Buy
2023-08-31 Eingeleitet H.C. Wainwright Buy
2022-05-24 Eingeleitet Cantor Fitzgerald Overweight
2020-05-26 Eingeleitet BTIG Research Buy
2020-05-26 Eingeleitet BofA/Merrill Buy
2020-05-26 Eingeleitet Jefferies Buy
2020-05-26 Eingeleitet William Blair Outperform
Alle ansehen

Lyra Therapeutics Inc Aktie (LYRA) Neueste Nachrichten

pulisher
May 22, 2025

Petri Dish: Thermo Fisher’s new partner; Waters buys California company - The Business Journals

May 22, 2025
pulisher
May 20, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

May 20, 2025
pulisher
May 20, 2025

US Stocks Likely To Open Lower After S&P 500's Six-Day Streak: 'Quick Recoveries Tend To See Stocks Rally More Over The Next 3-12 Months,' Says ExpertASP Isotopes (NASDAQ:ASPI) - Benzinga

May 20, 2025
pulisher
May 20, 2025

Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga

May 20, 2025
pulisher
May 19, 2025

Lyra Therapeutics Announces Reverse Stock Split Decision - TipRanks

May 19, 2025
pulisher
May 14, 2025

Lyra Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 14, 2025
pulisher
May 09, 2025

Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 09, 2025
pulisher
May 08, 2025

JPMorgan Chase & Co. Has $32,000 Stake in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World

May 08, 2025
pulisher
May 08, 2025

JPMorgan Chase & Co. Has $40,000 Stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) - Defense World

May 08, 2025
pulisher
May 07, 2025

Lyra Therapeutics to Present 52-Week Extension Stage Results for Enlighten 1 Phase 3 Study for Lyr-210 for the Treatment of Chronic Rhinosinusitis At Cosm 2025 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times

May 07, 2025
pulisher
May 07, 2025

Lyra Therapeutics Reports Positive Safety and Efficacy Results for LYR-210 in Phase 3 Extension Study for Chronic Rhinosinusitis - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Lyra Therapeutics to Present 52-week Extension Stage - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

Lyra Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView

May 07, 2025
pulisher
May 07, 2025

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewswire Inc.

May 07, 2025
pulisher
May 06, 2025

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Receives $1.25 Consensus Target Price from Analysts - Defense World

May 06, 2025
pulisher
May 06, 2025

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 06, 2025
pulisher
May 04, 2025

JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

May 04, 2025
pulisher
May 04, 2025

Geode Capital Management LLC Has $183,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World

May 04, 2025
pulisher
May 04, 2025

Ascendiant Capital Markets Predicts VMAR Q1 Earnings - Defense World

May 04, 2025
pulisher
Apr 30, 2025

Lyra Therapeutics Inc (LYRA) expanding its growth trajectory ahead - Sete News

Apr 30, 2025
pulisher
Apr 30, 2025

Financial Fitness Check: Examining B. Riley Financial Inc (RILY)’s Key Ratios - DWinneX

Apr 30, 2025
pulisher
Apr 29, 2025

Rhinitis Pipeline 2025: Groundbreaking Clinical Advancements - openPR.com

Apr 29, 2025
pulisher
Apr 29, 2025

Keeping an Eye on Lyra Therapeutics Inc (LYRA) After Insider Trading Activity - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

Lyra Therapeutics Inc (LYRA) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com

Apr 29, 2025
pulisher
Apr 29, 2025

What was Lyra Therapeutics Inc (LYRA)’s performance in the last session? - uspostnews.com

Apr 29, 2025
pulisher
Apr 29, 2025

Recent Insider Activity Could Benefit Schrodinger Inc (SDGR) - knoxdaily.com

Apr 29, 2025
pulisher
Apr 28, 2025

Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace

Apr 28, 2025
pulisher
Apr 28, 2025

Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Tuesday - The AM Reporter

Apr 28, 2025
pulisher
Apr 27, 2025

Lyra Therapeutics (LYRA) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News

Apr 27, 2025
pulisher
Apr 25, 2025

iCoreConnect Inc [ICCT] Shares Fall Approximately -87.86% Over the Year - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Lyra Therapeutics Inc [LYRA] Shares Rise 7.02 % on Thursday - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

QBTS Stock Sees Surge of Approximately 14.13% in Last Five Days - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Deckers Outdoor Corp [DECK] Records 200-Day SMA of $160.33 - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Shopify Inc [SHOP] Records 50-Day SMA of $99.94 - knoxdaily.com

Apr 25, 2025
pulisher
Apr 24, 2025

Analysts Say Lyra Therapeutics Inc (NASDAQ:LYRA) Can Really Get To 0.5 In 12 Months - Marketing Sentinel

Apr 24, 2025
pulisher
Apr 22, 2025

An Analysis of Lyra Therapeutics Inc (LYRA)’s Potential Price Growth - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Take off with Lyra Therapeutics Inc (LYRA): Get ready for trading - Sete News

Apr 22, 2025
pulisher
Apr 21, 2025

Is Lyra Therapeutics Inc (LYRA) worth investing in despite its undervalued state? - uspostnews.com

Apr 21, 2025
pulisher
Apr 11, 2025

Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $1.25 - Defense World

Apr 11, 2025
pulisher
Apr 08, 2025

Lyra Therapeutics stock hits 52-week low at $0.1 By Investing.com - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Lyra Therapeutics stock hits 52-week low at $0.1 - Investing.com

Apr 08, 2025
pulisher
Apr 03, 2025

TCBI Stock Sees Decline of Approximately -2.19% in Last Five Days - knoxdaily.com

Apr 03, 2025
pulisher
Apr 01, 2025

Technical analysis of Lyra Therapeutics Inc (LYRA) stock chart patterns - uspostnews.com

Apr 01, 2025
pulisher
Mar 31, 2025

Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 31, 2025
pulisher
Mar 28, 2025

Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline - Investing.com Australia

Mar 28, 2025
pulisher
Mar 27, 2025

PTCT Stock Sees Decline of Approximately -2.93% in Last Five Days - knoxdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Lyra Therapeutics Inc (LYRA) deserves deeper analysis - uspostnews.com

Mar 26, 2025
pulisher
Mar 21, 2025

A Closer Look at Lyra Therapeutics Inc (LYRA) Stock Gains - investchronicle.com

Mar 21, 2025
pulisher
Mar 19, 2025

Lyra Therapeutics stock plunges to 52-week low of $0.16 By Investing.com - Investing.com Australia

Mar 19, 2025

Finanzdaten der Lyra Therapeutics Inc-Aktie (LYRA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$581.44
price down icon 0.60%
$1.39
price up icon 6.92%
$32.50
price down icon 0.28%
$289.00
price down icon 1.22%
$4.2299
price up icon 5.48%
$72.69
price down icon 1.89%
Kapitalisierung:     |  Volumen (24h):